Anti-chloride Intracellular Channel Protein 1 (CLIC1) Antibodies Induce Tumour Necrosis and Angiogenesis Inhibition on In Vivo Experimental Models of Human Renal Cancer

• Published in: Anticancer research 2022-03, Vol.42 (3), p.1313-1325
• Main Authors: Radu-Cosnita, Andrei Dan, Nesiu, Alexandru, Berzava, Patricia Lorena, Cerbu, Simona, Cosma, Andrei, Comsa, Serban, Sarb, Simona, Ferician, Adela Maria, Ferician, Ovidiu Catalin, Cimpean, Anca Maria
• Format: Article
• Language: English
• Subjects: Angiogenesis; Angiogenesis Inhibitors - pharmacology; Animals; Antibodies; Antineoplastic Agents, Immunological - pharmacology; Blood vessels; Cancer; Carcinoma, Renal Cell - blood supply; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - metabolism; Carcinoma, Renal Cell - pathology; Cell Proliferation - drug effects; Chick Embryo; Chloride Channels - antagonists & inhibitors; Chloride Channels - metabolism; Chlorides; Chorioallantoic membrane; Cornea; Growth rate; Intracellular; Kidney cancer; Kidney Neoplasms - blood supply; Kidney Neoplasms - drug therapy; Kidney Neoplasms - metabolism; Kidney Neoplasms - pathology; Male; Metastases; Molecular Targeted Therapy; Necrosis; Neovascularization, Pathologic; Proteins; Rabbits; Renal cell carcinoma; Signal Transduction; Therapeutic targets; Time Factors; Tumor Burden - drug effects; Tumors; Xenograft Model Antitumor Assays; Xenografts; Xenotransplantation
• ISSN: 0250-7005; 1791-7530
• DOI: 10.21873/anticanres.15599

Chloride intracellular channel protein 1 (CLIC1) is known as a promoter of cancer progression, metastasis, and angiogenesis. Thus, CLIC1 could be a future therapeutic target. This study aimed to evaluate the effect of anti-CLIC1 antibodies on tumour cells and vessels of human renal cell carcinoma (RCC) in rabbit cornea and chick embryo chorioallantoic membrane (CAM) models. Human cc-RCC xenografts on rabbit cornea and CAM surface were performed. Anti-CLIC1 antibodies were applied for 5 consecutive days on both tumor models. We comparatively evaluated treated and untreated tumors by combining ultrasonography with microscopic techniques. RCC implants rapidly recruited blood vessels and had an exponential growth rate on both tumor models. Anti-CLIC1 antibodies suppressed tumor growth by inducing tumor cell necrosis. Tumor vessels regressed rapidly but not completely during anti-CLIC1 antibodies based therapy. Anti-CLIC1 antibodies induced tumor necrosis and tumor vasculature regression in human cc-RCC xenografts in both in vivo experimental models.